Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corporation is projected to experience significant revenue growth, with Corneal Health expected to advance by 9.4% for FY26, particularly in the latter half of the year as reimbursement for Epioxa improves. The company's innovative iDose pharmaceutical implant is seeing increased sales, contributing to a gross margin of 85.1%, which reflects an improvement of 280 basis points year-over-year and surpasses market expectations. Additionally, revenue from the iStent platform is estimated to have risen approximately 7% year-over-year, reinforcing Glaukos's positive financial outlook with revised revenue estimates of $205 million for FY26, driven by the anticipated growth in repeat administration patients for its products.

Bears say

Glaukos Corporation reported robust domestic glaucoma revenue of $86 million, which outperformed consensus expectations, and showcased a substantial year-over-year growth of 54%. However, the company has lowered its sales growth projections due to increasing challenges in the minimally invasive glaucoma surgery (MIGS) market internationally and a deceleration in U.S. growth, alongside revised adjusted earnings per share forecasts for 2026 and 2027 reflecting expected losses. Concerns regarding the potential for slower market adoption of its products, heightened competition, and possible unfavorable changes in the reimbursement landscape contribute to a pessimistic outlook for the firm's financial performance.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.